Quest for the right Drug

|
עמוד הבית / קולכיצין 0.5 מ"ג / מידע מעלון לרופא

קולכיצין 0.5 מ"ג COLCHICINE 0.5 mg (COLCHICINE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליה : TABLETS

Interactions : אינטראקציות

4.5   Interaction with other medicinal products and other forms of interaction

Interactions with other drugs are not or scarcely documented. Given the nature of the side effects, caution is advised with concomitant administration of drugs that can affect the blood count or have a negative effect on hepatic and/or renalfunction.

In addition, substances such as cimetidine and tolbutamide may reduce metabolism of colchicine and thus increase plasma levels of colchicine.

Colchicine is a substrate for both CYP3A4 and the transport protein P-gp. In the presence of CYP3A4 or P-gp inhibitors, the concentrations of colchicine inthe blood may increase. Toxicity, including fatal cases, have been reported during concurrent use of inhibitors such as macrolides (clarithromycin and erythromycin), ciclosporin, ketoconazole, itraconazole, voriconazole, HIV protease inhibitors, calcium channel antagonists such as verapamil and diltiazem. It has been reported that co- administration of azithromycin with colchicine leads to increased serum levels of colchicine. During treatment with azithromycin and after discontinuation, clinical follow-up, and potentially follow-up of serum levels of colchicine, is required (see section 4.4).

Grapefruit juice may increase plasma levels of colchicine. Grapefruit juice should therefore not be taken together with colchicine.

If treatment with a P-gp inhibitor (e.g. ciclosporin, verapamil or quinidine) or strong CYP3A4 inhibitor (e.g. ritonavir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketaconazole) is required in patients with normal renal or hepatic function, adjustment of colchicine dosage may be necessary.
Concurrent use of such inhibitors and colchicine should be avoided in patients with renal or hepatic damage (see section 4.4).
Reversible malabsorption of cyanocobalamine (Vitamin B12) may be inducedby an altered function of the intestinal mucosa.

The risk of myopathy and rhabdomyolysis is increased by a combination of colchicine with statins, fibrates, ciclosporin or digoxin.

שימוש לפי פנקס קופ''ח כללית 1994 Acute gouty arthritis, familial mediterranean fever (FMF)
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

RAFA LABORATORIES LTD

רישום

016 73 24811 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

30.08.21 - עלון לרופא

עלון מידע לצרכן

07.08.22 - עלון לצרכן אנגלית 28.02.22 - עלון לצרכן עברית 28.02.22 - עלון לצרכן ערבית 30.08.21 - החמרה לעלון

לתרופה במאגר משרד הבריאות

קולכיצין 0.5 מ"ג

קישורים נוספים

RxList WebMD Drugs.com